Granules India US Facility Receives FDA EIR with No Action Status

Granules India Limited announced that its US step-down subsidiary, Granules Consumer Health, LLC, has received an Establishment Inspection Report (EIR) with a No Action Indicated (NAI) status from the US Food and Drug Administration (FDA). The inspection was conducted at the company’s packaging facility located in Manassas, Virginia, from December 1 to 3, 2025. This marks the facility’s second FDA inspection, following a similar audit in March 2023, which also concluded with zero observations.

The filing does not disclose specific financial terms or payment structures related to the FDA inspection or its outcomes. The focus remains on the regulatory compliance and operational aspects of the facility.

The Manassas facility plays a critical role in Granules India’s operations as a packaging and distribution site. It processes controlled substances and over-the-counter (OTC) products across three advanced packaging lines. The facility is responsible for packaging both OTC and prescription (Rx) products and serves as a distribution hub for OTC products across the US. The successful inspection reflects the company’s adherence to quality and regulatory standards.

The inspection and its outcome are significant in the context of Granules India’s global operations. The company leverages its manufacturing efficiencies, regulatory compliance, and integrated supply chain to serve as a front-end division for OTC products in the US. This development underscores the company’s commitment to maintaining high standards in its packaging and distribution processes.

The FDA inspection was conducted over three days, from December 1 to 3, 2025. The facility had previously undergone an FDA audit in March 2023, which also concluded with zero observations. This consistent performance highlights the facility’s compliance with regulatory requirements and its importance in Granules India’s operational framework.

Granules India Limited, incorporated in 1991, is a vertically integrated pharmaceutical company headquartered in Hyderabad. The company is involved in the manufacturing of the entire pharmaceutical value chain, including Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), Finished Dosages (FDs), and Peptides CDMO. Granules India’s products are distributed to over 300 customers in regulated and semi-regulated markets, with a global presence extending to over 80 countries. The company operates 11 manufacturing facilities, with regulatory approvals from various international bodies, including the US FDA, EDQM, EU GMP, and others.